Drug profile · INN
fluticasone furoate + umeclidinium + vilanterol
TRELEGY ELLIPTA 100/62.5/25
fluticasone furoate + umeclidinium + vilanterol (TRELEGY ELLIPTA 100/62.5/25) is an FDA-listed pharmaceutical active ingredient. Associated with GlaxoSmithKline.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — fluticasone furoate + umeclidinium + vilanterol
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
fluticasone furoate + umeclidinium + vilanterol (TRELEGY ELLIPTA 100/62.5/25) is an FDA-listed pharmaceutical active ingredient. Associated with GlaxoSmithKline.
Key facts
INN fluticasone furoate + umeclidinium + vilanterol
Brand TRELEGY ELLIPTA 100/62.5/25
Originator GlaxoSmithKline
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is fluticasone furoate + umeclidinium + vilanterol?
fluticasone furoate + umeclidinium + vilanterol (TRELEGY ELLIPTA 100/62.5/25) is an FDA-listed pharmaceutical active ingredient. Associated with GlaxoSmithKline.
What is the brand name for fluticasone furoate + umeclidinium + vilanterol?
TRELEGY ELLIPTA 100/62.5/25 is a marketed brand name for fluticasone furoate + umeclidinium + vilanterol. Check FDA Drugs@FDA for the current US label holder and prescribing information.